Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Healthtrust
US Army
McKinsey
McKesson
QuintilesIMS
Chubb
Medtronic
Federal Trade Commission

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,264,923

« Back to Dashboard

Which drugs does patent 6,264,923 protect, and when does it expire?

Patent 6,264,923 protects ALVESCO and ZETONNA and is included in two NDAs.

This patent has one patent family member in one country.
Summary for Patent: 6,264,923
Title: Medicinal aerosol formulation of ciclesonide and related compounds
Abstract:A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
Inventor(s): Oliver; Martin J. (Clarendon Park, GB), Fatania; Kanu M. (Loughborough, GB), Scott; John S. (Loughborough, GB), Muller; Helgert (Radolfzell, DE)
Assignee: 3M Innovative Properties Company (St. Paul, MN)
Application Number:09/440,797
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Delivery;

Drugs Protected by US Patent 6,264,923

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-002 Jan 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-003 Jan 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,264,923

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Chile 2004001325 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Deloitte
Queensland Health
Dow
UBS
Cantor Fitzgerald
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.